Document is current

Article History

Received: 29 April 2025

Accepted: 21 July 2025

First Online: 11 August 2025

Declarations

:

: Thomas J. Müller has received honoraria for lectures from: AstraZeneca, Bristol-Myers Squibb, Janssen, Servier, Eli Lilly, Zeller Medical, Mepha, Lundbeck, Otsuka, Sunovion, Schwabe Pharma, Takeda and Sandoz. He is or was a consultant to: Eli Lilly, Lundbeck, Otsuka, Takeda, Sunovion, Bristol-Myers Squibb, AstraZeneca, Schwabe Pharma and Janssen. Arnaud Künzi declared, that the analysis was supported by Schwabe Pharma AG Grant through a grant. Ellen Heitlinger declared, that the medical writing was supported by Schwabe Pharma AG through a grant. Bernd Krämer has received honoraria for lectures from Schwabe. Roland von Känel has received honoraria from Heel Germany. Josef Hättenschwiler declared no interests. Matthias Hilpert declared no interests. Christian Imboden has received honoraria for advice and educational activities from Lundbeck, Schwabe, Janssen, Servier and OM Pharma. Edith Holsboer-Trachsler declared no interests. In the past three years, Siegfried Kasper has served as a consultant or on advisory boards for Angelini, Biogen, Boehringer, Esai, Janssen, IQVIA, Mylan, Otsuka Inc., Recordati, Rovi, and Schwabe; and he has served on speakers bureaus for Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Recordati, Schwabe, Servier, and Sothema. In the past three years, Martin Hatzinger has been on the speakers’ board of Idorsia, Janssen, Lundbeck and Schwabe Pharma. In the past 36 months, Borwin Bandelow has been on the speakers’ board for Aris, Lundbeck, Schwabe and Servier and on the advisory board for Cannaxan and Schwabe. Erich Seifritz has received grants from the Swiss National Science Foundation and the University of Zürich and honoraria for advice and educational activities from Lundbeck, Schwabe, Janssen, Otsuka, Mepha Pharma, Otsuka Pharma, Recordati, OM Pharma, Takeda, Sunovion Pharma and Angelini.